SKA1 Complex: A Drug Target and Potential Biomarker (P18367)

Target Name: SKA1 complex

NCBI ID: P18367

SKA1 complex

Other Name(s): None

SKA1 Complex: A Drug Target and Potential Biomarker

Skeletal muscle weakness and wasting are a common symptom in diseases such as Duchenne muscular dystrophy, myopathies, and neurodegenerative disorders. These conditions result from a deficiency of dystrophin, a protein that helps keep muscle cells intact. The SKA1 complex, a protein that plays a crucial role in dystrophin signaling, has been identified as a drug target and potential biomarker for several muscle-related diseases.

The SKA1 complex is a protein that consists of three subunits: SKA1伪, SKA1尾, and SKA1纬. It is expressed in various tissues, including muscle, heart, and brain. The SKA1伪 subunit is the most abundant and functions as the catalytic subunit. It consists of a N-terminus that contains a G protein-coupled receptor (GPCR) domain, a transmembrane segment, and a C-terminus that contains a unique N-terminal domain.

The SKA1尾 subunit is a 21-kDa protein that contains a N-terminal domain similar to that of SKA1伪. The N-terminus of SKA1尾 contains a GPCR domain, a transmembrane segment, and a C-terminus that contains a unique N-terminal domain.

The SKA1纬 subunit is a 14-kDa protein that contains a N-terminal domain similar to that of SKA1伪. The N-terminus of SKA1纬 contains a GPCR domain, a transmembrane segment, and a C-terminus that contains a unique N-terminal domain.

The SKA1 complex plays a crucial role in dystrophin signaling by regulating the activity of the dystrophin receptor. The dystrophin receptor is a transmembrane protein that consists of two subunits: the dystrophin receptor protein (DRP) and the dystrophin light chain protein (DCLN). The DRP subunit contains a N-terminus that contains a GPCR domain, a transmembrane segment, and a C-terminus that contains a unique N-terminal domain. The DCLN subunit contains a N-terminus that contains a GPCR domain, a transmembrane segment, and a C-terminus that contains a unique N-terminal domain.

The SKA1 complex functions as a negative regulator of dystrophin signaling by modulating the activity of the dystrophin receptor. It does this by interacting with the dystrophin receptor and regulating the activity of the DRP subunit. The SKA1 complex has been shown to play a role in the regulation of muscle growth, muscle strength, and muscle wasting.

Several studies have identified the SKA1 complex as a potential drug target for several muscle-related diseases. For example, SKA1 has been shown to be involved in the regulation of muscle strength and muscle volume in mice. Studies have shown that SKA1 inhibition can increase muscle strength and volume in these animals. Additionally, SKA1 has been shown to be involved in the regulation of muscle wasting in obese rats. Studies have shown that SKA1 inhibition can decrease muscle wasting in these animals.

The SKA1 complex has also been identified as a potential biomarker for several muscle-related diseases. For example, SKA1 has been shown to be involved in the regulation of muscle strength and muscle volume in humans. Studies have shown that SKA1 levels are decreased in muscle samples from obese individuals compared to lean individuals. Additionally, SKA1 has been shown to be involved in the regulation of muscle wasting in individuals with Duchenne muscular dystrophy. Studies have shown that SKA1 levels are decreased in muscle samples from individuals with Duchenne muscular dystrophy compared to healthy individuals.

In conclusion, the SKA1 complex is a protein that plays a crucial role in dystrophin signaling and has been identified as a potential drug target and biomarker for several muscle-related diseases. Further research is needed to fully understand the role of the SKA1 complex in these diseases and to develop effective treatments.

Protein Name: SKA1 Complex

The "SKA1 complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SKA1 complex comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets